|
Given the strong efficacy of Augment phase 3 data coupled with their strong interest in ortho-biologics, all these companies would be extremely keen on buying this technology..this could easily fetch at least a $1 billion price tag, given the potential size of this extremity fusion market...(roughly $50 a share = $1 billion/20 million shares)...
Sentiment : Strong Buy Rating :
 (No ratings) |
 |
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
0.05